Catalent gaining over 12% after investor call 🚀

6:30 PM 19 May 2023

Catalent (CTLT.US) is rising as much as 12% to $36.3 after the company assured investors that its challenges are temporary, while formally cutting its full-year guidance during the much-delayed investor call.

Catalent is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies, and consumer health products. Company slashed fiscal full-year outlook and delayed quarterly earnings report announcing that adjusted EBITDA would be in the range of $725 million to $775 million, down from the earlier projection of $1.22 billion to $1.3 billion. CEO Alessandro Maselli acknowledged that the company had been overly optimistic about annual growth and had failed to reduce costs promptly after rapid expansion during the pandemic. Despite remaining the worst performer among S&P 500 healthcare stocks in May, Catalent's shares are gaining significantly today.

The challenges faced by Catalent, including compliance issues and lower biotech funding, have impacted its financial performance. The company received a notice of non-compliance with listing requirements from the New York Stock Exchange due to a delayed filing. Catalent is still working on completing its fiscal Q3 report. Furthermore, the company's growth prospects have been shaken, with declining takeover interest. The recent events have caused investor sentiment to reach an all-time low, with doubts about the company's operational and forecasting capabilities.

Catalent stock price (CTLT.US), D1, source: xStation 5

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits